The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy

Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preser...

Descripción completa

Detalles Bibliográficos
Autores principales: McADAM, LAURA C., MAYO, AMANDA L., ALMAN, BENJAMIN A., BIGGAR, W. DOUGLAS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore SpA 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440807/
https://www.ncbi.nlm.nih.gov/pubmed/22655512
Descripción
Sumario:Deflazacort is the most commonly prescribed corticosteroid for the treatment of Duchenne muscular dystrophy in Canada. We review the long term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and cataract formation. The Canadian experience supports the use of deflazacort in treating boys with Duchenne muscular dystrophy.

Ejemplares similares